Kiran

Kiran biotech is an Italian private biotechnology startup developing targeted therapeutic platforms and biologics for oncology and other areas of high unmet medical need. Its lead technology, AvidinOX, is a patented tissue-anchoring platform designed to localize biotinylated therapeutic agents such as radiopharmaceuticals, monoclonal antibodies, chemotherapeutics, and therapeutic cells, with the goal of improving precision and reducing systemic exposure. The company is also advancing proprietary human antibodies, including anti-HER3 and anti-PD-L1 candidates, and maintains phage display-derived antibody libraries and peptide/protein discovery capabilities. Kiran biotech appears to be focused primarily on translational and preclinical development, licensing, and co-development rather than commercial-stage products. The company is based in Rome, with operational laboratories at the University of Rome Tor Vergata.